Research to Shift Raw Materials Dependent on Overseas Sources to a Domestic Base
Research institutes are introducing propagation and cultivation technologies aimed at changing the supply structure of medicinal plants that have relied on imports or wild harvesting. Asarum patens, the source plant of seshin, now has a method for stable propagation through tissue culture; pretreatment technology has also been proposed to improve the growth of Artemisia annua and the productivity of the key ingredient in antimalarial treatment; and two Ungernia species have shown that laboratory-grown cultures could become an alternative means of producing useful compounds.
This trend goes beyond the mere accumulation of research achievements and stems from the recognition that unstable raw material procurement has become a bottleneck for the entire bio and traditional Korean medicine industries. If cultivation can be standardized and alternative production becomes possible, industrial raw materials can be supplied at consistent quality while reducing overharvesting of rare resources, helping to ease the structural conflict between conservation and commercialization.
Making Standards and Quality Control More Scientific
The management system for herbal medicinal materials is also shifting from one centered on experience and customary practice to one based on data and verification. The quality control testing method for musk is being changed to directly measure preservative components; the drafting and review guidelines for revising herbal medicine (crude drug) standards have been organized to require genetic, compositional, and toxicity data in determining source species; and the case involving the manufacture and sale of 8.4 tons of illegal herbal medicinal materials revealed that gaps in on-site management can undermine trust in the actual market.
These adjustments signal that herbal medicinal materials have entered a stage where they can no longer circulate on the basis of tradition alone. Precisely proving the identity and safety of raw materials is essential to maintaining both public standards and market trust, and this carries major institutional significance because the same standards can also be applied to future exports and industrial expansion.
A Direction in Which Regional Industries Link Raw Materials to Exports
Local governments are making it clear that they aim to develop medicinal and natural-product industries not through support for individual items, but by tying them together as regional ecosystem businesses. Gangwon State’s annual exports reached $3.062 billion last year, and amid an ongoing reorganization centered on medical bio and cosmetics, the full amendment bill to Gyeonggi Province’s ordinance on fostering and supporting the green bio industry seeks to institutionalize a framework linking raw material procurement with commercialization. Yeongju City is sending a total of 10 tons of local agricultural specialty products, including red ginseng and bugak, to the U.S. market, while appointments at the Jecheon Korean Medicine and Natural Products Industry Promotion Foundation have also become a subject of scrutiny regarding the region’s capacity to operate its core industries.
Behind this is the judgment that regional industries cannot grow through research and development alone, and that raw material production, processing, certification, and export channels must function together. This can be seen as a move to redefine natural products and traditional medicine resources not merely as regional traditional industries, but as industrial assets equipped with supply chains and export strategies.
Growing Debate Over Organizational Restructuring Behind the Competition for Results
As the industry grows, conflict is also increasing over which organizations should take exclusive charge of it. Opposition surrounding the possible integration of the National Institute for Korean Medicine Development and the Korea Health Industry Development Institute shows differing views on whether Korean medicine should be regarded as an independent industry or absorbed as part of the broader health industry. In the private sector, integrated strategies that bundle research and development (R&D), securing functional raw materials, manufacturing, and global international certification within a single company are also gaining strength.
In the public sector, the movement is caught between efficiency and identity, while in the private sector, companies are moving toward vertical integration to secure speed and consistency. Ultimately, the core of this trend is the reality that the natural products and Korean medicine industries can no longer compete effectively under a loose division-of-labor structure, and who controls raw materials, standards, and commercialization authority is likely to shape the future industrial landscape.